Atara Q3 net loss $4.3M; cash $13.7M; tab-cel BLA PDUFA Jan 10, 2026

Atara Biotherapeutics, Inc.

2025-Q3 EPS reported $2.93 vs consensus -$0.88 ▲ beat (+434.0%)

Cash and equivalents $13.7M as of Sep 30, 2025, down from $22.3M at Jun 30.
Net loss of $4.3M ($0.32 per share) vs. $21.9M loss a year ago.
Total revenues $3.5M, down from $40.2M in Q3 2024 due to deferred revenue recognition.
Workforce reduced ~29% in Oct 2025; ~15 employees now retained.
FDA accepted tab-cel BLA with Priority Review; $40M milestone due from Pierre Fabre upon approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.